News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Image
Image

Media Contact:

Robert Murphy

Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:
Email:
robert.murphy@otsuka-us.com
Press Release

Otsuka announces that interim data from a Phase 2b/c trial exploring quabodepistat (QBS), in combination with delamanid and bedaquiline, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients. QBS is an investigational anti-tuberculosis compound which has a new mechanism of action that interferes with the cell-wall structure of the bacteria causing TB.

Press Release

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck U.S., the U.S. subsidiaries of H. Lundbeck A/S,  presented new post hoc pooled analyses of two pivotal Phase 3 trials evaluating the safety and efficacy of REXULTI® (brexpiprazole) in patients with agitation associated with dementia due to Alzheimer’s disease.1 The posters were presented on March 16  at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting in Atlanta.

Press Release

Otsuka Pharmaceutical Co., Ltd. announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd. and its U.S. subsidiary, Sumitomo Pharma America, Inc.

US News

Otsuka’s Economic and Health Impact in the United States report is now available. The report highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., McQuade Center for Strategic Research & Development, and Otsuka Precision Health, Inc., formerly known as Otsuka Digital Health, Inc.